HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Shitrit, D. Articles by Kramer, M. R. Search for Related Content PubMed PubMed Citation Articles by Shitrit, D. Articles by Kramer, M. R.

Pulmonary Mycobacterium kansasii Infection in Israel, 1999–2004^*

Clinical Features, Drug Susceptibility, and Outcome

^* From the Pulmonary Institute (Drs. D. Shitrit, Shlomi, Daniele, and Kramer), Rabin Medical Center, Beilinson Campus, Petah Tiqwa; Israel Lung Association (Dr. Baum), Tel Aviv; Macabbi Medical Service (Ms. Priess and Dr. Raz), Tuberculosis Center, Rehovot; Public Health Tel Aviv (Ms. Lavy), Israel Ministry of Health, Tel Aviv; and Department of Internal Medicine (Dr. A. B-G. Shitrit), Shaare-Zedek Medical Center, Jerusalem, Israel.

Correspondence to: Mordechai R. Kramer, MD, Pulmonary Institute, Rabin Medical Center, Beilinson Campus, Petah Tiqwa 49100, Israel; e-mail: davids3{at}clalit.org.il

Abstract

Background: Mycobacterium kansasii infection is one of the most common causes of nontuberculous mycobacterial lung disease in world. However, little is known about its background characteristics or drug sensitivity in nonendemic areas.

Design: We assessed the clinical features, radiologic findings, and drug sensitivity associated with M kansasii infection in Israel.

Methods: Patients with a culture-positive diagnosis of M kansasii infection between April 1999 and April 2004 were identified from a clinic database of tuberculosis centers. Mycobacterial cultures were performed with standard methods. Data on patient background and clinical features were collected from the medical files.

Results: Mean age (± SD) of the 56 patients was 58 ± 18 years, and 64% were men; 59% had associated lung disease. Fifteen percent were receiving immunosuppressive medications. None had HIV infection. Systemic comorbid diseases were noted in 27%. The most common clinical presentations were chest pain, cough, hemoptysis, fever, and night sweats. Cavitation was noted only in 54%. Older patients had more noncavitary disease than younger patients (p = 0.01, r = 0.35). Lower-lobe predominance was very rare (4%). None of the patients presented with pleural effusion or lymphadenopathy. Only seven patients (11%) underwent bronchoscopy for diagnosis. M kansasii isolates showed the highest sensitivity to rifampin, ethambutol, clarithromycin, and ofloxacin, and the highest resistance to ciprofloxacin and capreomycin. The mean duration of treatment was 21 ± 7.2 months. There were no disease-related deaths.

Conclusions: M kansasii disease in Israel has no association with HIV, more systemic comorbid diseases and associated lung disease, and fewer cavitations. Following appropriate treatment, patients with M kansasii disease have an excellent prognosis.

Key Words: cavitation • drug sensitivity • Mycobacterium kansasii

This article has been cited by other articles:

				J. Glassroth Pulmonary Disease Due to Nontuberculous Mycobacteria Chest, January 1, 2008; 133(1): 243 - 251. [Abstract] [Full Text] [PDF]